Synthesis of zinc oxide nanoparticles using methanol propolis extract (Pro-ZnO NPs) as antidiabetic and antioxidant.
Humans
Antioxidants
/ pharmacology
Zinc Oxide
/ chemistry
Propolis
/ pharmacology
Methanol
Hypoglycemic Agents
/ pharmacology
alpha-Glucosidases
Nanoparticles
/ chemistry
Ascomycota
Diabetes Mellitus
Plant Extracts
/ pharmacology
alpha-Amylases
Metal Nanoparticles
/ chemistry
Anti-Bacterial Agents
/ pharmacology
Microbial Sensitivity Tests
Journal
PloS one
ISSN: 1932-6203
Titre abrégé: PLoS One
Pays: United States
ID NLM: 101285081
Informations de publication
Date de publication:
2023
2023
Historique:
received:
07
05
2023
accepted:
12
07
2023
medline:
27
7
2023
pubmed:
25
7
2023
entrez:
25
7
2023
Statut:
epublish
Résumé
In recent times, the overall health of individuals has been declining due to unhealthy lifestyles, leading to various diseases, including diabetes. To address this issue, antidiabetic and antioxidant agents are required to back-up human well-being. Zinc oxide (ZnO) is one such substance known for its antidiabetic and antioxidant effects. To enhance its capability and effectiveness, propolis was utilized to synthesize zinc oxide nanoparticles (Pro-ZnO NPs). The objective of this study was to synthesize Pro-ZnO NPs and assess their performance by conducting inhibition assays against α-amylase and α-glucosidase enzymes, as well as a 2,2-diphenyl-1-picrylhydrazyl (DPPH) free radical scavenging assay. The results showed that Pro-ZnO NPs were formed in a hexagonal wurtzite structure, with particle sizes ranging from 30 to 50 nm and an absorption band observed at 341 nm. The stability, chemical properties, and crystallography of Pro-ZnO NPs were also thoroughly examined using appropriate methods. The Pro-ZnO NPs demonstrated significant inhibitory effects against α-amylase and α-glucosidase enzymes, with inhibition rates reaching 69.52% and 73.78%, respectively, whereas the antioxidant activity was as high as 70.76%. Consequently, with their high inhibition rates, the Pro-ZnO NPs demonstrate the potential to be employed as a natural agent for combating diabetes and promoting antioxidant effects.
Identifiants
pubmed: 37490488
doi: 10.1371/journal.pone.0289125
pii: PONE-D-23-13871
pmc: PMC10368249
doi:
Substances chimiques
Antioxidants
0
Zinc Oxide
SOI2LOH54Z
Propolis
9009-62-5
Methanol
Y4S76JWI15
Hypoglycemic Agents
0
alpha-Glucosidases
EC 3.2.1.20
Plant Extracts
0
alpha-Amylases
EC 3.2.1.1
Anti-Bacterial Agents
0
Types de publication
Journal Article
Langues
eng
Sous-ensembles de citation
IM
Pagination
e0289125Informations de copyright
Copyright: © 2023 P. D. et al. This is an open access article distributed under the terms of the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original author and source are credited.
Déclaration de conflit d'intérêts
The authors have declared that no competing interests exist.
Références
Sci Rep. 2020 Jul 30;10(1):12805
pubmed: 32732959
Lancet Diabetes Endocrinol. 2014 Jan;2(1):56-64
pubmed: 24622669
IET Nanobiotechnol. 2019 Sep;13(7):736-741
pubmed: 31573543
Nanomaterials (Basel). 2020 Apr 16;10(4):
pubmed: 32316212
Evid Based Complement Alternat Med. 2013;2013:670451
pubmed: 23710228
J Photochem Photobiol B. 2019 Aug;197:111541
pubmed: 31272033
Luminescence. 2023 Jul;38(7):1139-1148
pubmed: 35362206
Food Chem. 2012 Dec 1;135(3):960-6
pubmed: 22953811
J Funct Biomater. 2022 Oct 28;13(4):
pubmed: 36412848
Int J Nanomedicine. 2018 Jun 21;13:3571-3591
pubmed: 29950836
Sci Rep. 2021 Jan 21;11(1):1974
pubmed: 33479338
Biochem Biophys Rep. 2021 Apr 08;26:100995
pubmed: 33898767
Materials (Basel). 2015 Oct 29;8(11):7278-7308
pubmed: 28793638
J Ethnopharmacol. 2019 Dec 5;245:112173
pubmed: 31445129
J Anim Sci Biotechnol. 2019 Jul 9;10:57
pubmed: 31321032
Int J Food Sci Nutr. 2015 Feb;66(1):58-62
pubmed: 25578761
Molecules. 2021 Aug 12;26(16):
pubmed: 34443474
Arch Biochem Biophys. 2004 Aug 15;428(2):204-8
pubmed: 15246878
RSC Adv. 2022 Feb 16;12(10):5816-5833
pubmed: 35424565
Trends Biotechnol. 2016 Jul;34(7):588-599
pubmed: 26944794
RSC Adv. 2020 Jun 23;10(40):23899-23907
pubmed: 35517333
Artif Cells Nanomed Biotechnol. 2018;46(sup1):1210-1220
pubmed: 29533101
Int J Nanomedicine. 2018 Dec 20;14:87-100
pubmed: 30587987
J Food Sci Technol. 2011 Aug;48(4):412-22
pubmed: 23572765
Nat Prod Res. 2018 Oct;32(20):2418-2423
pubmed: 29258353
Adv Pharmacol Sci. 2013;2013:308249
pubmed: 24382957
Biochem Biophys Res Commun. 2017 Dec 16;494(3-4):587-593
pubmed: 29079190
BMC Complement Med Ther. 2020 Jan 29;20(1):22
pubmed: 32020870
Molecules. 2017 Jun 08;22(6):
pubmed: 28594362
Eur J Prev Cardiol. 2019 Dec;26(2_suppl):7-14
pubmed: 31766915
Chem Cent J. 2007 Jun 07;1:13
pubmed: 17880743
Appl Nanosci. 2020;10(8):3057-3074
pubmed: 32421069
Sci Rep. 2020 Feb 26;10(1):3445
pubmed: 32103090
Artif Cells Nanomed Biotechnol. 2020 Dec;48(1):1068-1078
pubmed: 32815404
Acta Naturae. 2014 Jan;6(1):35-44
pubmed: 24772325
Front Cell Infect Microbiol. 2021 Apr 29;11:640225
pubmed: 33996624